Headlines about Cytori Therapeutics (NASDAQ:CYTX) have been trending positive on Tuesday, according to Alpha One Sentiment. The research firm, a unit of Accern, identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Alpha One ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cytori Therapeutics earned a news sentiment score of 0.29 on Alpha One’s scale. Alpha One also gave news articles about the biotechnology company an impact score of 100 out of 100, indicating that recent news coverage is extremely likely to have an effect on the company’s share price in the immediate future.

Here are some of the media stories that may have effected AlphaOne’s rankings:

A number of analysts have weighed in on the stock. B. Riley restated a “buy” rating and issued a $6.75 target price on shares of Cytori Therapeutics in a research report on Thursday, February 16th. Maxim Group raised their target price on shares of Cytori Therapeutics from $6.00 to $10.00 and gave the company a “buy” rating in a research report on Wednesday, February 15th. Finally, Zacks Investment Research lowered shares of Cytori Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, February 20th.

Shares of Cytori Therapeutics (NASDAQ:CYTX) traded down 5.014664% during mid-day trading on Tuesday, reaching $0.997346. 608,408 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $1.54 and a 200 day moving average price of $1.65. Cytori Therapeutics has a 52-week low of $0.98 and a 52-week high of $5.44. The firm’s market cap is $23.51 million.

Cytori Therapeutics (NASDAQ:CYTX) last posted its quarterly earnings results on Thursday, March 23rd. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.01. Cytori Therapeutics had a negative net margin of 314.07% and a negative return on equity of 172.63%. The business earned $1.50 million during the quarter, compared to the consensus estimate of $3.36 million. During the same period last year, the firm earned ($0.03) EPS. The business’s revenue for the quarter was down 6.3% on a year-over-year basis. Analysts forecast that Cytori Therapeutics will post ($1.08) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.dailypolitical.com/2017/04/18/cytori-therapeutics-cytx-earns-media-impact-score-of-0-29.html.

About Cytori Therapeutics

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

5 Day Chart for NASDAQ:CYTX

Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.